SCHEMBL4354969

SCHEMBL4354969

Nc1nc(N(Br)c2ccccc2)c2cc(-c3cnn(CC4OCCO4)c3)ccc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.39
PIK3CD O00329 4/20 0.39
PIK3CB P42338 4/20 0.39
PI4KA P42356 4/20 0.39
PIK3CG P48736 4/20 0.39
PI4KB Q9UBF8 4/20 0.39
FGFR1 P11362 5/20 0.36
FGFR3 P22607 5/20 0.36
KDR P35968 5/20 0.36
FGFR2 P21802 4/20 0.36
FGFR4 P22455 4/20 0.36
IKBKE Q14164 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
FAAH O00519 1/20 0.35
ACSS2 Q9NR19 1/20 0.34
EGLN1 Q9GZT9 4/20 0.33
MTOR P42345 1/20 0.32
ATM Q13315 1/20 0.32
ATR Q13535 1/20 0.32
PIP5K1C O60331 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354962 0.83 PIK3CD (0.54) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4357374 0.82 PIK3CD (0.50) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4355921 0.81 PRMT5 (0.43) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4355195 0.80 PIK3CD (0.46) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4362395 0.80 PRMT5 (0.45) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4358324 0.79 PIK3CA (0.42) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4354964 0.76 EGFR (0.46) KDRIKBKETBK1
SCHEMBL4353964 0.75 DHFR (0.50) PIK3CAPI4KAPI4KB
SCHEMBL4360359 0.74 EGLN1 (0.42) PIK3CAPIK3CDPIK3CBPI4KAPIK3CG
SCHEMBL4354901 0.74 SRC (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US claimed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US claimed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US claimed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US claimed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US claimed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 PIK3CA 3986/4885PIK3CD 4161/4885PIK3CB 4068/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 PIK3CA 3986/4885PIK3CD 4161/4885PIK3CB 4068/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 PIK3CA 4078/4885PIK3CD 4183/4885PIK3CB 4278/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 PIK3CA 3799/4885PIK3CD 3942/4885PIK3CB 4011/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 PIK3CA 3799/4885PIK3CD 3942/4885PIK3CB 4011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.